Industry leaders discussed how AI is revolutionizing sectors like travel, enterprise, pharmaceuticals, and investment by enhancing personalization, productivity, and innovation while emphasizing the importance of measurable business outcomes and cautious adoption. They highlighted the transformative potential of AI companions, secure governance, and iterative development, acknowledging both the opportunities and risks in this profound technological revolution.
The panel discussion on the future of AI brought together leaders from diverse industries to explore how artificial intelligence is transforming business and innovation. Johannes from GetYourGuide highlighted how AI has accelerated growth and profitability for their travel experience platform by managing a vast and complex inventory of local suppliers and multilingual content. He emphasized that AI enables better personalization and search relevance, moving away from undifferentiated listings to more tailored consumer experiences. Johannes sees AI companions and agents as game changers for the travel industry, akin to the impact the iPhone had on mobile technology.
Eléonore from Pigment discussed AI adoption in enterprise settings, focusing on integrating AI seamlessly into daily workflows to enhance productivity without adding complexity. She stressed the importance of automating painful tasks for individual contributors, particularly in supply chain teams, and measuring success through adoption, accuracy, productivity gains, and business outcomes. Pigment employs multiple large language models (LLMs) like OpenAI, Anthropic, and Gemini, carefully selecting and testing them to ensure they deliver real value rather than rushing to adopt every new technology.
Shobie from GSK shared insights from the pharmaceutical industry, where AI is used to shorten drug development timelines and improve R&D productivity. He compared technologists to carpenters who control their medium, while pharmacists are like gardeners working with nature, highlighting the challenges of innovation in pharma. AI helps GSK identify new scientific hypotheses, target clinical trials more effectively, and accelerate the discovery-to-market process. Shobie emphasized that technology must serve the core mission of delivering medicines to patients, cautioning against adopting tech for tech’s sake.
Matt, a venture investor, pointed out the risks companies face when adopting AI too quickly without proper governance, especially regarding data security and information sharing. He introduced NEXOS, a platform that helps enterprises manage AI usage securely and efficiently, ensuring sensitive data does not leave the organization unintentionally. Matt also discussed the commoditization of LLMs, comparing them to cloud infrastructure, where the real value lies in building applications on top of these models. He noted that while AI is revolutionary, there is a risk of a bubble with some companies failing, but overall, the technology will drive significant change.
Throughout the discussion, the panelists agreed on the importance of focusing on measurable business outcomes such as revenue growth, productivity improvements, and adoption rates rather than technology for its own sake. They highlighted the evolving landscape of AI tools, including AI assistants widely used by engineers and scientists, and the trend toward early prototyping and iterative development. The conversation concluded with a consensus that while AI adoption involves challenges and risks, it represents a profound revolution with the potential to transform industries and improve lives globally.